IVOSIDENIB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H22ClF3N6O3
Molecular Weight	582.961
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of IVOSIDENIB

Structure Search

SMILES

FC1=CN=CC(=C1)N([C@H](C(=O)NC2CC(F)(F)C2)C3=CC=CC=C3Cl)C(=O)[C@@H]4CCC(=O)N4C5=NC=CC(=C5)C#N

InChI

InChIKey=WIJZXSAJMHAVGX-DHLKQENFSA-N

InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C28H22ClF3N6O3
Molecular Weight	582.961
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:49:08 UTC 2023` Edited by `admin` on `Sat Dec 16 10:49:08 UTC 2023`
Record UNII	Q2PCN8MAM6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IVOSIDENIB

Official Name

English

TIBSOVO

Brand Name

English

GLYCINAMIDE, 1-(4-CYANO-2-PYRIDINYL)-5-OXO-L-PROLYL-2-(2-CHLOROPHENYL)-N-(3,3-DIFLUOROCYCLOBUTYL)-N2-(5-FLUORO-3-PYRIDINYL)-, (2S)-

Systematic Name

English

IVOSIDENIB [USAN]

Common Name

English

AG-120

Code

English

ivosidenib [INN]

Common Name

English

IVOSIDENIB [MI]

Common Name

English

Ivosidenib [WHO-DD]

Common Name

English

IVOSIDENIB [ORANGE BOOK]

Common Name

English

(2S)-N-{(1S)-1-(2-Chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

562216

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

FDA ORPHAN DRUG

739720

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

FDA ORPHAN DRUG

938423

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

FDA ORPHAN DRUG

637718

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

EU-Orphan Drug

EU/3/16/1802

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

NCI_THESAURUS

C137826

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

FDA ORPHAN DRUG

481515

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

Code System Code Type Description

CAS

1448347-49-6

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

DRUG BANK

DB14568

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

WIKIPEDIA

Ivosidenib

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

DAILYMED

Q2PCN8MAM6

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

PUBCHEM

71657455

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

FDA UNII

Q2PCN8MAM6

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

CHEBI

145430

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

INN

10225

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

RXCUI

2049873

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

MERCK INDEX

m12089

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

SMS_ID

100000175066

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

LACTMED

Ivosidenib

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

NCI_THESAURUS

C114383

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

USAN

EF-21

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

DRUG CENTRAL

5292

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

EPA CompTox

DTXSID801027928

Created by admin on Sat Dec 16 10:49:08 UTC 2023 , Edited by admin on Sat Dec 16 10:49:08 UTC 2023

PRIMARY

Related Record Type Details


					MFS7RWZ7PI

ISOCITRATE DEHYDROGENASE (NADP) CYTOPLASMIC R132C

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INDUCER

Comments:

The following dose modifications are recommended: Strong CYP3A inducers: Avoid concomitant use.


					Q2PCN8MAM6

EXCRETED UNCHANGED

Qualification:

FECAL

Amount:


					0B98U0ML4X

ISOCITRATE DEHYDROGENASE (NADP) CYTOPLASMIC

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					FD64E4H8NW

ISOCITRATE DEHYDROGENASE (NADP) CYTOPLASMIC R132L

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					1G99NX98JJ

ISOCITRATE DEHYDROGENASE (NADP) CYTOPLASMIC R132S

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					Q2PCN8MAM6

EXCRETED UNCHANGED

Qualification:

URINE

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> INHIBITOR

Comments:

The following dose modifications are recommended: Strong CYP3A inhibitors: Reduce dose to 250 mg QD


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE


					89IU583S89

ISOCITRATE DEHYDROGENASE (NADP) CYTOPLASMIC R132G

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Amount:


					9STQ04T9G6

ISOCITRATE DEHYDROGENASE (NADP) CYTOPLASMIC R132H

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Comments:

The following dose modifications are recommended: Sensitive CYP3A substrates: Avoid concomitant use.

Interaction Type:

MAJOR

Related Record Type Details


					Q2PCN8MAM6

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC
Volume of Distribution	PHARMACOKINETIC